The Current Ratio as of November 2024 (TTM) for Eliem Therapeutics, Inc. (ELYM) is 60.41

According to Eliem Therapeutics, Inc.’s latest financial reports and current stock price. The company's current Current Ratio is 60.41. This represents a change of 38.25% compared to the average of 43.70 of the last 4 quarters.

Eliem Therapeutics, Inc. (ELYM) Historical Current Ratio (quarterly & annually)

How has ELYM Current Ratio performed in the past?

The mean historical Current Ratio of Eliem Therapeutics, Inc. over the last ten years is 23.98. The current 60.41 Current Ratio has changed 25.09% with respect to the historical average. Over the past ten years (40 quarters), ELYM's Current Ratio was at its highest in in the June 2024 quarter at 60.41. The Current Ratio was at its lowest in in the March 2020 quarter at 0.

Eliem Therapeutics, Inc. (ELYM) Current Ratio by Quarter and Year

Discovering the peaks and valleys of Eliem Therapeutics, Inc. Current Ratio, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.

Eliem Therapeutics, Inc. (ELYM) Average Current Ratio

How has ELYM Current Ratio performed in the past?

The current Current Ratio of Eliem Therapeutics, Inc. (ELYM) is greater than its 3-year, greater than its 5-year, and greater than its 10-year historical averages

Eliem Therapeutics, Inc. (ELYM) Current Ratio vs. Peers

How is ELYM’s Current Ratio compared to its peers?

Eliem Therapeutics, Inc.’s Current Ratio is greater than PMV Pharmaceuticals, Inc. (13.98), greater than MediciNova, Inc. (16.66), greater than Pharvaris N.V. (19.08), greater than PepGen Inc. (8.47), greater than Anebulo Pharmaceuticals, Inc. (3.45), greater than Rezolute, Inc. (13.79), greater than HCW Biologics Inc. (0.07), greater than Molecular Partners AG (14.33), greater than Aerovate Therapeutics, Inc. (8.78), greater than Adagene Inc. (2.50), greater than Acrivon Therapeutics, Inc. Common Stock (12.75), greater than AN2 Therapeutics, Inc. (9.75), greater than Cyteir Therapeutics, Inc. (21.89), greater than Pardes Biosciences, Inc. (9.81), greater than Shattuck Labs, Inc. (7.96), greater than Champions Oncology, Inc. (0.69), greater than Century Therapeutics, Inc. (10.39),

Build a custom stock screener for Eliem Therapeutics, Inc. (ELYM) and other stocks

One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Eliem Therapeutics, Inc. using the financials and key metrics that matter to you in a single view.

The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:

Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.

Get your free trial here.

Eliem Therapeutics, Inc. (ELYM) and other stocks custom spreadsheet templates

The easiest way to analyze a company like Eliem Therapeutics, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.

Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.

Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.